---

Carol Lynch

Global Head of Biopharmaceuticals, Sandoz

Judges praised Carol for her role in the biosimilars industry and in the launch of the first US biosimilar. She joined Sandoz in 2014 and is focused on leading efforts in the development, manufacture and commercialization of biosimilars. In February 2016, she was elected as Chair of Medicines for Europe’s (formerly the EGA’s) European Biosimilars Group, where she will be working to improve stakeholder awareness and understanding of, and confidence in biosimilars and advocating for policies that support the growth of the biosimilars industry.

---

Part of the Power List 2016

The Top 100

The nominations are in and after considerable debate and analysis from our judging panel, we present The Power List 2016 – our second foray into the Top 100 most influential people in the world of drug development and manufacture.

Go to The Power List 2016